Skip to main content

Menu

BNFC October 2025 Update

This update contains 7 significant changes, 5 new monographs and 1 deleted monograph

Significant Changes:

  • Charcoal, activated: name change to activated charcoal.
  • Digoxin-specific antibody: name change to digoxin-specific antibody fragments.
  • Factor VIII fraction, dried: name change to factor VIII.
  • Factor XIII fraction, dried: name change to factor XIII.
  • Fenfluramine: new indication and dose for Lennox-Gastaut syndrome and update to structure of existing dosing for Dravet syndrome.
  • Guidance included on biotin interference with laboratory tests (advice in biotin, levothyroxine sodium, liothyronine sodium, parenteral nutrition supplements, vitamins with minerals and trace elements; see example in levothyroxine sodium).
  • Respiratory syncytial virus immunisation: updated guidance for immunisation of infants and children.

New Monographs:

  • Adtralza® [tralokinumab].
  • Alyftrek® [deutivacaftor with tezacaftor and vanzacaftor].
  • Beyfortus® [nirsevimab].
  • Hympavzi® [marstacimab].
  • Jakavi® [ruxolitinib].

 

Deleted Monographs: Hepatitis A with typhoid vaccine.

Environment: dev